Please login to the form below
Halaven
This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.
NICE set to reject wider use of Eisai’s Halaven
NICE set to reject wider use of Eisai’ s Halaven. Issues draft guidance recommending against second-line use in breast cancer. ... Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to
Latest news
-
NICE backs Eisai's Halaven for breast cancer
NICE backs Eisai's Halaven for breast cancer. Reverses 2012 rejection due to new data and patient access discount. ... NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug.
-
Lilly closes on first approval for sarcoma drug Lartruvo
If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
-
Eisai gets green light for Lenvima in kidney cancer
Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
-
Oncology directions
Halaven (eribulin).
-
Disappointment for pharma with new Cancer Drugs Fund list
While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster
More from news
Approximately 8 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “ ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who
-
Country report: The healthcare market in Japan
The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Medical Writer
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Senior Programme Executive
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Account Manager – Med Comms – London
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
Subscribe to our email news alerts
PMHub
CMR
Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
